Heart Failure Clinical Trials

Find Heart Failure Clinical Trials Near You

Clinical Value of Novel Echocardiographic Biomarkers Assessing the Myocardial Work in Heart Failure

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY

This study seeks to investigate the clinical value of novel echocardiographic indices, including myocardial work parameters, during the acute phase of heart failure hospitalization. The trajectory of novel echocardiographic indices from the start to the end of hospitalization will be captured, as a means to unravel and subsequently better understand the diverse pathophysiology of different phenotypes of the heart failure continuum. Correlation between novel echocardiographic indices with clinical data, biochemical data, different heart failure phenotypes, and therapeutic maneuvers will be attempted. Prognostic implications of those indices will be explored.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patients acutely admitted at the Department of Cardiology of AHEPA University General Hospital, Thessaloniki, Greece with symptoms and/or signs of heart failure (HF), as those are defined by the European Society of Cardiology.

• Patients with abnormal plasma concentration of N-terminal pro-B-type natriuretic peptide, measured within 24 hours from admission

• Objective echocardiographic evidence of cardiac structural and/or functional abnormalities consistent with the presence of left ventricular (LV) systolic dysfunction/diastolic dysfunction/raised LV filling pressures upon admission assessment

Locations
Other Locations
Greece
AHEPA University Hospital, Thessaloniki, Greece
RECRUITING
Thessaloniki
Contact Information
Primary
Stylianos Daios, MD, MSc
stylianoschrys.daios@gmail.com
6947529606
Backup
Vasileios Anastasiou, MD, MSc
vasianas44@gmail.com
6978223907
Time Frame
Start Date: 2022-04-10
Estimated Completion Date: 2025-01-10
Participants
Target number of participants: 300
Treatments
Heart failure with reduced ejection fraction
Left Ventricular Ejection Fraction of ≤40%
Heart failure with mid-range ejection fraction
Left Ventricular Ejection Fraction of 41-49%
Heart failure with preserved ejection fraction
Left Ventricular Ejection Fraction of ≥50%
Related Therapeutic Areas
Sponsors
Leads: Aristotle University Of Thessaloniki

This content was sourced from clinicaltrials.gov